Mucosolvan Junior (Ambroxol Hydrochloride)

Ambroxol acts on the respiratory epithelium by breaking down mucus glycoproteins, stimulating surfactant production and enhancing ciliary movement. These actions reduce mucus viscosity and promote faster clearance of bronchial secretions.

The appropriate dose of Mucosolvan Junior is determined by the prescribing healthcare professional based on the child’s age, weight and clinical condition. Patients should follow the prescriber’s instructions and the product label.

Safety data for ambroxol in pregnancy and lactation are limited. Women who are pregnant or breastfeeding should discuss potential risks and benefits with their physician before using Mucosolvan Junior.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mucosolvan Junior’s active ingredient, ambroxol, works by directly modifying mucus properties and enhancing ciliary activity, whereas some alternatives (e.g., guaifenesin) primarily increase airway fluid volume. Ambroxol may provide faster mucus clearance, but choice depends on patient age, tolerance and physician preference.

Store the oral suspension at ambient temperature below 25 °C, in its original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use if the product shows signs of degradation.

Mucosolvan Junior is taken orally, usually using a calibrated measuring device or spoon as directed by the prescriber. The suspension should be shaken gently before each dose to ensure uniform distribution of the active ingredient.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, skin disorders like Stevens‑Johnson syndrome, and significant liver enzyme elevations. Immediate medical attention is required if any of these symptoms appear.

Mucosolvan Junior should be avoided in children under 2 years of age unless a physician specifically recommends it, and in individuals with known hypersensitivity to ambroxol or any excipients. Patients with severe renal impairment should also seek medical advice before use.